Antihypertensives
ACE inhibitors, ARBs and direct vasodilators for first- and second-line management of essential hypertension.
- 14 SKUs Tablets · 30/100
- Generics + Originator Rx
We distribute 240+ pharmaceutical SKUs across six therapeutic areas — selected for their public-health impact, prescribed daily by physicians, and trusted by the patients who rely on them.
ACE inhibitors, ARBs and direct vasodilators for first- and second-line management of essential hypertension.
Atorvastatin, rosuvastatin and combination therapies for hypercholesterolaemia and post-MI secondary prevention.
DOACs, LMWH and VKA for atrial fibrillation, VTE prophylaxis and treatment.
Metformin, sulfonylureas, DPP-4 inhibitors and SGLT2 inhibitors for type 2 diabetes management.
Human insulin, rapid- and long-acting analogues, premixed formulations. Full cold-chain handled.
Injectable and once-weekly formulations for type 2 diabetes and chronic weight management.
SSRIs, SNRIs, atypicals and adjunctive therapies for major depressive disorder and anxiety.
First- and second-generation antipsychotics including long-acting injectables for schizophrenia and bipolar disorder.
Narrow- and broad-spectrum anticonvulsants for focal and generalised seizure disorders.
ICS, LABA, LAMA and triple-combination inhalers for asthma and COPD maintenance.
Second-generation non-sedating antihistamines for allergic rhinitis and chronic urticaria.
Intranasal steroids for allergic and non-allergic rhinitis, including paediatric formulations.
Omeprazole, pantoprazole, esomeprazole and dexlansoprazole for GERD, PUD and H. pylori eradication.
Ursodeoxycholic acid, silymarin and Essentiale formulations for chronic liver conditions.
5-ASA, immunosuppressants and biologics for Crohn's disease and ulcerative colitis.
Tyrosine kinase inhibitors and monoclonal antibodies for solid tumours, handled in dedicated cold-chain protocols.
Check-point inhibitors and supportive therapies managed by qualified pharmacists and oncology nurses.
Orphan-designated therapies distributed via named-patient and early-access programmes.
If you are a manufacturer evaluating distribution for a molecule in our portfolio areas — or an adjacent one — we would be glad to share a confidential feasibility note.
We respond to qualified manufacturer inquiries within two business days. Brief, transparent, no-nonsense — tell us about the molecule and the markets.